We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+20.31%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$460M
AUM Growth
-$24.7M
Cap. Flow
-$63.4M
Cap. Flow %
-13.79%
Top 10 Hldgs %
55.03%
Holding
52
New
9
Increased
6
Reduced
21
Closed
13

Top Buys

1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$24.2M
2
EIGR
Eiger BioPharmaceuticals, Inc.
EIGR
+$16.9M
3
AGN
Allergan plc
AGN
+$15.9M
4
SIEN
Sientra, Inc.
SIEN
+$10.1M
5
HRTX icon
Heron Therapeutics
HRTX
+$8.99M

Top Sells

1
IOVA icon
Iovance Biotherapeutics
IOVA
+$41.7M
2
CPRX icon
Catalyst Pharmaceutical
CPRX
+$13.4M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.2M
4
ADMS
Adamas Pharmaceuticals
ADMS
+$11.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$11.5M

Sector Composition

1 Healthcare 78.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NEOS
51
DELISTED
Neos Therapeutics, Inc
NEOS
– –
-1,611,999
Closed -$4.21M
NVLN
52
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
– –
-729,301
Closed -$897K
1 2
3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Broadfin Capital held 52 positions worth $460M, down 5.1% from $484M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Broadfin Capital withdrew a net $63.4M in Q2 2019, closing 13 positions and reducing 21 holdings. Its most notable exit was Aclaris Therapeutics, an estimated $12.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 82% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Allergan plc worth $19.2M.

  • Broadfin Capital's largest Q2 2019 buy was Allergan plc: 114,804 shares worth $19.2M.
  • Broadfin Capital added most to Biohaven Pharmaceutical Holding Company Ltd. in Q2 2019, an estimated $24.2M increase.
  • Broadfin Capital's biggest Q2 2019 reduction was Iovance Biotherapeutics, cutting an estimated $41.7M.
  • Broadfin Capital fully exited Aclaris Therapeutics in Q2 2019, selling an estimated $12.2M.
  • Broadfin Capital's ten largest holdings make up 55% of its $460M portfolio in Q2 2019.
  • Broadfin Capital opened 9 new positions and closed 13 in Q2 2019.
  • Broadfin Capital's portfolio value fell 5.1% quarter-over-quarter to $460M.

Based on Broadfin Capital's 13F filing for Q2 2019, filed 14 Aug 2019.